All In Biotech

Drug Trial Radar · NCT07173478

A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis (Phase 3 Trial)

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Oct 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Sep 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • OPA-15406Drug

    1% foam, topical, twice daily, for 4 weeks

  • VehicleDrug

    vehicle, topical, twice daily, for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success rate in Investigator's Global Assessment (IGA)Time frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mita Dermatology Clinic

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.